文献速递肺外科

最高纵隔淋巴结转移对pN2非小细胞肺癌生存的倾向性匹配分析

Propensity-Matched Analysis of Clinical Relevance of the Highest Mediastinal Lymph Node Metastasis.
PubMed 文献 · Ann Thorac Surg · 2020-06-23

本研究回顾性纳入2004至2015年北京大学人民医院266例pT1-4N2M0非小细胞肺癌患者,其中HMLL阳性128例、阴性138例,经1:1倾向性评分匹配后109对。匹配前后HMLL阳性均未显示与更差总生存相关(匹配后校正HR=1.00,95%CI 0.70-1.42)。结论认为HMLL转移不提示更差生存,其临床意义需进一步研究。

要点

  • HMLL阳性与阴性患者匹配后总生存无显著差异(校正HR=1.00,95%CI 0.70-1.42)。
  • 匹配前HMLL阳性亦未显示更差生存(校正HR=1.21,95%CI 0.87-1.68)。
  • HMLL阳性组女性比例更高(P=.034)、腺癌比例更高(P=.003)。

核心结论

  • 在pT1-4N2M0非小细胞肺癌患者中,最高纵隔淋巴结转移未显示与更差总生存相关。

研究设计与样本

  • 回顾性队列研究,纳入2004至2015年北京大学人民医院行主要肺切除及系统淋巴结清扫的pT1-4N2M0非小细胞肺癌患者266例。
  • 采用1:1倾向性评分匹配,HMLL阳性组128例与阴性组138例匹配后得到109对。
  • 总生存采用Kaplan-Meier法估计、log-rank检验比较,多因素Cox回归分析风险因素,竞争风险分析评估癌症特异性死亡累积发生率。

主要发现

  • HMLL阳性组女性比例更高(P=.034)、腺癌比例更高(P=.003)。
  • 匹配前HMLL阳性与阴性组总生存无显著差异(校正HR=1.21,95%CI 0.87-1.68)。
  • 匹配后HMLL阳性与阴性组总生存仍无显著差异(校正HR=1.00,95%CI 0.70-1.42)。

临床怎么用

  • 对于pT1-4N2M0非小细胞肺癌,HMLL转移阳性不应单独作为判断预后更差的依据。
  • HMLL转移的临床意义尚需进一步研究确认,临床决策应综合其他因素。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical relevance of the highest mediastinal lymph node (HMLL) metastasis in patients with pathological N2 non-small cell lung cancer (NSCLC) is still controversial. Our study aimed to reassess the effect of HMLL metastasis on survival. METHODS: Patients with stage pT1-4N2M0 NSCLC who underwent major lung resection and systemic lymphadenectomy at Peking University People's Hospital from 2004 to 2015 were identified. Patients in the HMLL-positive group were matched to patients in the HMLL-negative group using 1:1 propensity score matching analysis. Overall survival was estimated by Kaplan-Meier method and compared using log-rank test, and multivariable Cox proportional hazard regression was constructed to identify risk factors associated with overall survival. The cumulative incidence of cancer specific mortality was evaluated through a competing risk analysis. RESULTS: A total of 266 NSCLC patients with stage pT1-4N2M0 NSCLC were enrolled. Of those, 128 cases were HMLL positive and 138 cases were HMLL negative. A higher proportion of patients in the HMLL-positive group were female (P = .034) and had a higher rate of adenocarcinoma (P = .003). Compared with the HMLL-negative, the HMLL-positive group was not associated with worse survival in unmatched cohorts (adjusted hazard ratio = 1.21; 95% confidence interval, 0.87-1.68). After propensity score matching, 109 pairs were selected. No survival difference remained in matched cohorts (adjusted hazard ratio = 1.00; 95% confidence interval, 0.70-1.42). CONCLUSIONS: Highest mediastinal lymph node metastasis does not exhibit worse survival in patients with stage pT1-4N2M0 NSCLC. The clinical relevance of HMLL metastasis needs further examination.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wang SD, Liu GW, Li X, et al. Propensity-Matched Analysis of Clinical Relevance of the Highest Mediastinal Lymph Node Metastasis. Ann Thorac Surg. 2020. PMID: 32585196. doi:10.1016/j.athoracsur.2020.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。